CPT code 0109U designates the MycoDART–PCR™ Aspergillus diagnostic panel, a proprietary molecular test that uses dual amplification real‑time PCR to detect four Aspergillus species in blood, bronchoalveolar lavage fluid, or tissue. This PLA code identifies a single manufacturer‑specific assay and is relevant nationally for hospitals, clinical laboratories, and payers managing testing for invasive fungal infections in immunocompromised patients. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what CPT code 0109U represents, the clinical context for testing (aspergillosis detection in at‑risk patients), typical sites of service (clinical laboratory processing of blood, lavage, or tissue specimens), and how this PLA code is used to uniquely track a manufacturer‑specific diagnostic assay. The publication provides benchmarks and policy context related to billing and coverage for proprietary molecular diagnostics, outlines common modifiers used with PLA and laboratory codes, and summarizes clinical implications for ordering providers and laboratories. Data not provided in the input—such as detailed payer-specific coverage policies, associated taxonomies, and ICD‑10 mappings—is noted as unavailable.